These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: 15-Deoxy-Δ12,14-prostaglandin J2 Inhibits Cell Migration on Renal Cell Carcinoma via Down-Regulation of Focal Adhesion Kinase Signaling.
    Author: Yamamoto Y, Koma H, Yagami T.
    Journal: Biol Pharm Bull; 2020; 43(1):153-157. PubMed ID: 31902920.
    Abstract:
    Renal cell carcinoma (RCC) is one of the chemoresistant cancers. There is a pressing need to establish therapeutic approaches to prevent RCC proliferation and metastasis. The electrophilic 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is an endogenous anti-cancerous agent. Treatment with high concentrations of 15d-PGJ2 is known to induce apoptosis of RCC cells, independent of the nuclear receptor, peroxisome proliferator-activated receptor-γ (PPARγ). In this study, we investigated the effects of 15d-PGJ2 on the metastatic properties of RCC Caki-2 cells. The metastatic potential of RCC was evaluated by measuring the migratory ability of Caki-2 cells. Although treatment with low concentrations of 15d-PGJ2 did not cause apoptosis, it did decrease the migration of Caki-2 cells in a concentration-dependent manner. PPARγ did not mediate the inhibitory effect of 15d-PGJ2 on the migration of Caki-2 cells. Treatment with a low concentration of 15d-PGJ2 resulted in disassembled focal adhesions and extensive filamentous actin reorganization. Furthermore, 15d-PGJ2 significantly reduced phosphorylation of focal adhesion kinase (FAK). In conclusion, 15d-PGJ2 attenuated the migratory ability of RCC, independent of PPARγ. Further, 15d-PGJ2 appeared to suppress cell migration via inactivation of FAK and subsequent disassembly of focal adhesion. Our present study highlights the therapeutic potential of 15d-PGJ2 for prevention of RCC metastasis.
    [Abstract] [Full Text] [Related] [New Search]